<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="264">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 08, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00907101</url>
  </required_header>
  <id_info>
    <org_study_id>US10127</org_study_id>
    <nct_id>NCT00907101</nct_id>
  </id_info>
  <brief_title>Evaluate Effectiveness of Epiduo® Gel in Reducing Antibiotic Sensitive &amp; Resistant Strains of Propionibacterium (P)Acnes</brief_title>
  <official_title>Evaluation of the Effectiveness of Epiduo® Gel (Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel) in Reducing Antibiotic Sensitive and Resistant Strains of P Acnes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma Laboratories, L.P.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma Laboratories, L.P.</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness of Epiduo® Gel in reducing
      antibiotic sensitive and resistant strains of P acnes in vivo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Change from baseline in quantitative bacteriology measurements at week 4</measure>
    <time_frame>Week 4</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability assessments</measure>
    <time_frame>Week 4</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>P Acnes Colonization</condition>
  <arm_group>
    <arm_group_label>Study Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel (Epiduo® Gel)
Other Names:
Epiduo® Gel Apply once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel (Epiduo® Gel)</intervention_name>
    <description>Apply once daily</description>
    <arm_group_label>Study Treatment</arm_group_label>
    <other_name>Epiduo® Gel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult male or female subjects 18 years of age and older, with no past or
             present history of any significant internal disease

          -  Subjects who:

               -  show a high degree of fluorescence of the facial skin under a Wood's lamp,
                  indicating the presence of  P acnes

               -  have Baseline P acnes count of &gt; 10,000 per cm2 CFU of the facial skin
                  (forehead)

               -  have high level resistance to erythromycin, variable resistance to clindamycin,
                  resistance to tetracycline and variable resistance to doxycycline and
                  minocycline

        Exclusion Criteria:

          -  Subjects who exhibit any skin disorders of an acute or chronic nature (e.g.,
             psoriasis, eczema, etc)

          -  Subjects who have taken topical or systemic antibiotics within 4 weeks prior to
             baseline assessments

          -  Subjects who have used other medications which may influence skin surface P acnes
             levels

          -  Subjects who are unwilling to refrain from using toners, astringents or other drying
             agents on the face during the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald W Gottschalk, MD</last_name>
    <role>Study Director</role>
    <affiliation>Galderma Laboratories, L.P.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Skin Study Center</name>
      <address>
        <city>Broomall</city>
        <state>Pennsylvania</state>
        <zip>19008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>October 1, 2012</lastchanged_date>
  <firstreceived_date>May 20, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adapalene</mesh_term>
    <mesh_term>Benzoyl Peroxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
